Overview

The pharmaceutical sector is a strategic priority for Angola as the country seeks to strengthen its health system, reduce dependence on imported medicines, and develop new non-oil industries. 

National policy, through the National Health Development Plan, PRODESI, the National Development Plan (PDN 2025) and the Angola 2050 Vision, aims to expand domestic pharmaceutical manufacturing capacity, promote local production of essential medicines, and modernise regulatory and quality-control systems. Efforts are underway to develop industrial facilities for basic generics, antibiotics, analgesics, antimalarials, injectables, medical consumables, and herbal-based products, alongside improved storage and distribution networks.

Institutional leadership is provided by the Ministry of Health (MINSA), the Ministry of Industry and Commerce, and the Regulatory Authority for Medicines and Health Technologies (ARMED). Private investment is emerging in segments such as generics production, medical supplies, packaging, and distribution logistics, supported by fiscal incentives under PRODESI for import-substituting industries.

Pharmaceuticals Tunisia

Economic contribution

Although still small, the pharmaceutical industry is becoming increasingly relevant for economic diversification and public health:

  • Angola imports the vast majority of medicines, creating substantial scope for import substitution in generics and basic medical products.
  • The sector supports a growing network of distributors, wholesalers, and pharmacy chains, contributing to urban service-sector employment.
  • Local manufacturing of selected medicines and medical consumables is expanding, particularly in Luanda and nearby industrial zones.
  • Pharmaceutical investment reduces vulnerability to external shocks, lowers long-term health-sector costs, and strengthens national drug security.

Outlook

The outlook for pharmaceuticals is positive, driven by rising demand, population growth, and policy commitments to build local capacity. Medium-term growth will depend on securing reliable inputs, improving electricity and water supply for industrial plants, and ensuring cost competitiveness relative to imports.

Challenges

  • High dependence on imported APIs and finished medicines, limiting local value addition.
  • Insufficient domestic production capacity, with only a few manufacturing sites currently operational.
  • Quality-control and regulatory gaps, requiring continued strengthening of ARMED and laboratory infrastructure.
  • High operating costs (energy, machinery, packaging) relative to established producers in Asia and North Africa.
  • Limited access to specialist skills in pharmaceutical engineering, GMP compliance, and industrial chemistry.
  • Fragmented distribution networks, especially outside Luanda.
  • Difficulty accessing finance for capital-intensive pharmaceutical facilities.

Opportunities

  • Local production of essential generics, including tablets, syrups, injectables, antimalarials, antibiotics, and chronic-disease medicines.
  • Manufacturing of medical consumables (syringes, gloves, IV sets, disinfectants) for hospitals and clinics.
  • Development of herbal and phytopharmaceutical products, leveraging Angola’s biodiversity.
  • Establishment of packaging and labelling industries to support medicine distribution.
  • Investment in cold-chain logistics, warehousing, and pharmaceutical-grade transport systems.
  • Potential for regional exports to SADC and AfCFTA markets as capacity improves.
  • Public-private partnerships in vaccine storage, diagnostics, and medical-device supply chains.